NCT04831242 (Meerkat) is a clinical trial in Neonatal Seizure, sponsored by Cambridge University Hospitals NHS Foundation Trust.

Who is sponsoring NCT04831242?

NCT04831242 is sponsored by Cambridge University Hospitals NHS Foundation Trust.

What condition does NCT04831242 study?

NCT04831242 studies Neonatal Seizure.

Is NCT04831242 still recruiting?

NCT04831242 is currently recruiting now. Last updated 18 April 2025.

Last reviewed 2025-04-18 · How we verify

NCT04831242: Meerkat

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring Key Activity and Physiology of Neonates in Intensive Care

Recruiting now Last updated 18 April 2025

What this trial tests

trial in Neonatal Seizure in 48 participants. Currently enrolling.

Timeline

1 August 2021

Primary endpoint
30 December 2026

31 December 2026

Quick facts

Lead sponsor	Cambridge University Hospitals NHS Foundation Trust
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	48
Start date	1 August 2021
Primary completion	30 December 2026
Estimated completion	31 December 2026
Sites	1 location across United Kingdom

Conditions studied

Neonatal Seizure — all drugs for Neonatal Seizure →

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Who can join

Eligibility, any sex, with Neonatal Seizure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To optimise and evaluate a novel non-contact physiological monitoring system in the neonatal intensive care unit (NICU)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Seizure

Currently open trials in the same condition.

NCT05610085 — A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures · Phase 2 · recruiting
NCT05361070 — Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy · active not recruiting

Other Cambridge University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04831242 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
Last refreshed: 18 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing